These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3530128)

  • 1. Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
    Joshi M; Anthony WC; Tenney JH; Drusano GL; Caplan ES; Standiford HC; Henson A; Warren JW
    Antimicrob Agents Chemother; 1986 Jul; 30(1):90-5. PubMed ID: 3530128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections.
    Horowitz EA; Preheim LC; Safranek TJ; Pugsley MP; Sanders CC; Bittner MJ
    Antimicrob Agents Chemother; 1985 Aug; 28(2):299-301. PubMed ID: 3914859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of moxalactam versus clindamycin/tobramycin in the treatment of mixed anaerobic/aerobic infections.
    Joshi M; Fitzpatrick BJ; Warren JW; Caplan ES; Tenney JH
    Am Surg; 1986 Sep; 52(9):467-71. PubMed ID: 3530075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.
    Gentry LO
    Pharmacotherapy; 1985; 5(5):254-67. PubMed ID: 3906585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients.
    Winston DJ; Ho WG; Bruckner DA; Gale RP; Champlin RE
    Am J Med; 1988 Jul; 85(1A):21-30. PubMed ID: 3041815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections.
    Giamarellou H; Perdikaris G; Galanakis N; Davoulos G; Mandragos K; Sfikakis P
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1362-7. PubMed ID: 2679374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections.
    Tally FP; Kellum JM; Ho JL; O'Donnell TF; Barza M; Gorbach SL
    Antimicrob Agents Chemother; 1986 Feb; 29(2):244-9. PubMed ID: 3717931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in some hemostatic parameters in patients with infections treated with ceftazidime and latamoxef.
    Gabryelewicz A; Prokopowicz J; Wołosowicz N; Czajkowski A; Dabrowska M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):398-407. PubMed ID: 2444514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime in treatment of urinary tract infection in patients with spinal cord injury: comparison with moxalactam.
    Montgomerie JZ; Gilmore DS; Canawati HN; Morrow JW
    Urology; 1990 Jan; 35(1):93-5. PubMed ID: 2404368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
    Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime review.
    Yost RL; Ramphal R
    Drug Intell Clin Pharm; 1985; 19(7-8):509-13. PubMed ID: 3896712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.
    de Pauw B; Williams K; de Neeff J; Bothof T; de Witte T; Holdrinet R; Haanen C
    Antimicrob Agents Chemother; 1985 Dec; 28(6):824-8. PubMed ID: 3909956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P; Ryan DM; Sowa MA; Watts CM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ; Simberkoff MS; Landesman SH
    J Infect Dis; 1984 Apr; 149(4):562-7. PubMed ID: 6725990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.
    Jones RN
    Infection; 1985; 13 Suppl 1():S81-8. PubMed ID: 3902652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
    Fitzpatrick BJ; Standiford HC
    Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.